Neoplasms

Respiratory Tract (Lung and Bronchial) Diseases

All Conditions

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma

Carcinoma, Bronchogenic

Bronchial Neoplasms

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Antineoplastic Agents

All Drugs and Chemicals

Tislelizumab

Antineoplastic Agents, Immunological

Patients completed radiotherapy alone or sequential chemoradiation with 42 days received consolidation Tislelizumab 200mg every 3 weeks for 12 months.

Rong Yu, MD

Wei Deng, MD

The current standard of care for locally advanced non-small cell lung cancer (NSCLC) is concurrent chemoradiation and consolidation immunotherapy. In real world clinical practice, patients who cannot tolerate concurrent chemoradiation generally received radiotherapy alone or sequential chemoradiation. These patients are more likely to develop distant metastases and therefore may require tolerable systemic consolidation regimens. However, there is a lack of evidence from clinical studies on consolidation immunotherapy after radiotherapy alone or sequential chemoradiation. The aim of the study is to explore the efficacy and safety of Tislelizumab consolidation therapy after radiotherapy or sequential chemoradiation in locally advanced NSCLC patients who are intolerable of concurrent concurrent chemoradiation.

Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

A Prospective, Open-label, Single-arm, Phase II Trial Investigating the Efficacy and Safety of Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients

Defined from the date of enrollment to the date of death or any recurrence.

Defined from the date of enrollment to the date of death.

Defined as the occurrence of a complete or partial response per RECIST 1.1 criteria.

Peking University Cancer Hospital & Institute

Professor

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients	NCT05758116	Non-small Cell ... Consolidation I... Radiotherapy or...	Tislelizumab	18 Years -	Peking University Cancer Hospital & Institute
Tislelizumab Consolidation Therapy After Radiotherapy or Sequential Chemoradiation in Locally Advanced NSCLC Patients	NCT05758116	Non-small Cell ... Consolidation I... Radiotherapy or...	Tislelizumab	18 Years -	Peking University Cancer Hospital & Institute

Spots Global Cancer Trial Database for radiotherapy or sequential chemoradiation